SEC Form SC 13G filed by Dynavax Technologies Corporation

3/4/22 4:02:21 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $DVAX alert in real time by email

SC 13G 1 dvax.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. _1__)* DYNAVAX TECHNOLOGIES CORPORATION (Name of Issuer) COMMON STOCK, PAR VALUE $.001 PER SHARE (Title of Class of Securities) 268158201 (CUSIP Number) DECEMBER 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [_] Rule 13d-1(b) [x] Rule 13d-1(c) [_] Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person?s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment co ntaining information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deeme d to be ?filed? for the purpose of Section 18 of the Securities Exchange Act of 1934 (?Act?) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). SCHEDULE 13G CUSIP No. 268158201 1 Names of Reporting Persons Chicago Capital LLC 2 Check the appropriate box if a member of a Group (see instructions) (a) [ ] (b) [ ] 3 Sec Use Only 4 Citizenship or Place of Organization Illinois Number of Shares Beneficially Owned by Each Reporting Person With: 5 Sole Voting Power 5,734,000 6 Shared Voting Power -0- 7 Sole Dispositive Power 5,734,000 8 Shared Dispositive Power -0- 9 Aggregate Amount Beneficially Owned by Each Reporting Person 5,734,000 10 Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) [ ] 11 Percent of class represented by amount in row (9) 4.7% 12 Type of Reporting Person (See Instructions) IA Item 1. (a) Name of Issuer: Dynavax Technologies Corporation, a Delaware corporation (the ?Issuer?). (b) Address of Issuer?s Principal Executive Offices: 2100 Powell Street, Suite 900 Emeryville, California 94608 Item 2. (a) Name of Person Filing: Chicago Capital LLC (b) Address of Principal Business Office or, if None, Residence: 135 South LaSalle Street Suite 4200 Chicago, IL 60603 (c) Citizenship: Illinois (d) Title and Class of Securities: common stock, par value $0.001 per share (?Common Stock?) (e) CUSIP No.: 268158201 Item 3. If this statement is filed pursuant to ?? 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: (a) [_] Broker or dealer registered under Section 15 of the Act; (b) [_] Bank as defined in Section 3(a)(6) of the Act; (c) [_] Insurance company as defined in Section 3(a)(19) of the Act; (d) [_] Investment company registered under Section 8 of the Investment Company Act of 1940; (e) [X] An investment adviser in accordance with Rule 13d-1(b)(1)(ii) (E); (f) [_] An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F); (g) [_] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G); (h) [_] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) [_] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940; (j) [_] A non-U.S. institution in accordance with Rule 240. 13d-1(b)(1)(ii)(J); (k) [_] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____ Item 4. Ownership (a) Amount Beneficially Owned: 5,734,000 (b) Percent of Class: 4.7% (c) Number of shares as to which such person has: (i) Sole power to vote or to direct the vote: 5,734,000 (ii) Shared power to vote or to direct the vote: -0- (iii) Sole power to dispose or to direct the disposition of: 5,734,000 (iv) Shared power to dispose or to direct the disposition of: -0- Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities , check the following [x]. Item 6. Ownership of more than Five Percent on Behalf of Another Person. Not applicable Item 7. Identification and classification of the subsidiary which acquired the security being reported on by the parent holding company or control person. Not applicable Item 8. Identification and classification of members of the group. Not applicable Item 9. Notice of Dissolution of Group. Not applicable Item 10. Certifications. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. By: Chicago Capital LLC, its Chief Compliance Officer Dated: 03/04/2022 /s/Stacey Sargent Name: Stacey Sargent Title: Chief Compliance Office Name/Title The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative (other than an executive officer or general partner of this filing person), evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature. Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001). Page 1 of 1 1297544.3

Get the next $DVAX alert in real time by email

Recent Analyst Ratings for

$DVAX

Date	Price Target	Rating	Analyst
2/11/2025	$15.00 → $12.00	Neutral → Sell	Goldman
2/1/2024	$20.00	Neutral	Goldman
9/27/2022	$22.00	Mkt Outperform	JMP Securities
1/6/2022	$38.00	Buy	Goldman
12/29/2021	$23.00 → $28.00	Buy	HC Wainwright & Co.
8/31/2021	$20.00 → $23.00	Buy	HC Wainwright & Co.
8/6/2021	$19.00	Buy	Goldman Sachs
8/5/2021	$16.00 → $20.00	Buy	HC Wainwright & Co.

More analyst ratings

SEC Form SC 13G filed by Dynavax Technologies Corporation

3/4/22 4:02:21 PM ET

$DVAX

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $DVAX alert in real time by email

Recent Analyst Ratings for

$DVAX

Date	Price Target	Rating	Analyst
2/11/2025	$15.00 → $12.00	Neutral → Sell	Goldman
2/1/2024	$20.00	Neutral	Goldman
9/27/2022	$22.00	Mkt Outperform	JMP Securities
1/6/2022	$38.00	Buy	Goldman
12/29/2021	$23.00 → $28.00	Buy	HC Wainwright & Co.
8/31/2021	$20.00 → $23.00	Buy	HC Wainwright & Co.
8/6/2021	$19.00	Buy	Goldman Sachs
8/5/2021	$16.00 → $20.00	Buy	HC Wainwright & Co.

More analyst ratings

SEC Form SC 13G filed by Dynavax Technologies Corporation

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$DVAX

SEC Form SC 13G filed by Dynavax Technologies Corporation

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$DVAX

$DVAX
Press Releases

Ciena Set to Join S&P 500; Arrowhead Pharmaceuticals to Join S&P MidCap 400; ADT and OneSpaWorld Holdings to Join S&P SmallCap 600

Sanofi to Acquire Dynavax, Adding a Marketed Adult Hepatitis B Vaccine and Phase 1/2 Shingles Candidate to the Pipeline

Dynavax to Participate at the 8th Annual Evercore Healthcare Conference

$DVAX
SEC Filings

SEC Form S-8 POS filed by Dynavax Technologies Corporation

SEC Form S-8 POS filed by Dynavax Technologies Corporation

SEC Form S-8 POS filed by Dynavax Technologies Corporation

$DVAX
Analyst Ratings

Dynavax downgraded by Goldman with a new price target

Goldman initiated coverage on Dynavax with a new price target

JMP Securities initiated coverage on Dynavax with a new price target

$DVAX
Insider Purchases

Director Myers Scott Dunseth bought $41,116 worth of shares (3,800 units at $10.82), increasing direct ownership by 12% to 35,004 units (SEC Form 4)

$DVAX
Insider Trading

SEC Form 4 filed by Large owner Deep Track Biotechnology Master Fund, Ltd.

Director Emini Emilio returned 10,075 units of Common Stock - Restricted Stock Units to the company, closing all direct ownership in the company (SEC Form 4)

Director Myers Scott Dunseth returned 31,204 units of Common Stock - Restricted Stock Units to the company, closing all direct ownership in the company (SEC Form 4)

$DVAX
Financials

Dynavax Reports Third Quarter 2025 Financial Results and Announces New $100 Million Share Repurchase Program

Dynavax to Report Third Quarter 2025 Financial Results and Host Conference Call on November 5, 2025

Dynavax Reports Second Quarter 2025 Financial Results

$DVAX
Leadership Updates

Ciena Set to Join S&P 500; Arrowhead Pharmaceuticals to Join S&P MidCap 400; ADT and OneSpaWorld Holdings to Join S&P SmallCap 600

Deep Track Capital Comments on ISS Recommendation

Leading Independent Proxy Advisory Firm ISS Recommends Stockholders Vote "FOR" All Four of Dynavax's Highly Qualified Director Nominees

$DVAX
Large Ownership Changes